BioCentury
ARTICLE | Company News

Humalys SAS, Vivalis deal

January 18, 2010 8:00 AM UTC

Vivalis acquired antibody company Humalys for €10.4 million ($15.1 million) in cash. Humalys' Humalex technology uses human B lymphocytes isolated directly from selected donors to identify and generat...